Single treatments that have lasting effects: Some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin

Journal of Psychiatry and Neuroscience

Volumn 38, Issue 2, 2013, Pages 78-83

  Young, Simon N ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; GLUTAMIC ACID; KETAMINE; METHYLPHENIDATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; PSILOCYBINE; PSYCHOTROPIC AGENT; ANESTHETIC AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; PSYCHEDELIC AGENT;

ABSENCE OF SIDE EFFECTS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; BASIC RESEARCH; BIOLOGICAL THERAPY; CLINICAL RESEARCH; DEPRESSION; DRUG MECHANISM; DRUG MEGADOSE; FACIAL EXPRESSION; HUMAN; HUMAN TISSUE; MOOD; MUSHROOM; NONHUMAN; NOTE; PROCESS OPTIMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; THERAPY EFFECT; TRANQUILIZING ACTIVITY; AFFECT; ANIMAL; ANXIETY DISORDERS; ATTITUDE; BEHAVIOR; DEPRESSIVE DISORDER; DRUG EFFECTS; PLACEBO EFFECT; TREATMENT OUTCOME;

AFFECT; ANESTHETICS, DISSOCIATIVE; ANIMALS; ANTI-ANXIETY AGENTS; ANTI-DYSKINESIA AGENTS; ANXIETY DISORDERS; ATTITUDE; BEHAVIOR; BOTULINUM TOXINS; DEPRESSIVE DISORDER; FACIAL EXPRESSION; HALLUCINOGENS; HUMANS; KETAMINE; PLACEBO EFFECT; PSILOCYBINE; TREATMENT OUTCOME;

EID: 84874323717     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.120128     Document Type: Note

References (43)

1. Vittengl JR, Clark LA, Dunn TW, et al. Reducing relapse and recurrence in unipolar depression: a comparative meta-analysis of cognitive-behavioral therapy's effects. J Consult Clin Psychol 2007; 75:475-88.
2. Wollmer MA, de Boer C, Kalak N, et al. Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res 2012;46:574-81.
3. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 2011;68:71-8.
4. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002;105:164-72.
5. Crane GE. Cyloserine as an antidepressant agent. Am J Psychiatry 1959;115:1025-6.
6. Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990;185:1-10.
7. Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012;62:63-77.
8. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351-4.
9. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856-64.
10. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010;67:793-802.
11. Zarate CA, Brutsche NE, Ibrahim L, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012;71:939-46.
12. Murrough JW. Ketamine as a novel antidepressant: from synapse to behavior. Clin Pharmacol Ther 2012;91:303-9.
13. Bunney BG, Bunney WE. Rapid-acting antidepressant strategies: mechanisms of action. Int J Neuropsychopharmacol 2012;15:695-713.
14. aan het Rot M, Zarate Jr CA, Charney DS, et al. Ketamine for depression: Where do we go from here? Biol Psychiatry 2012;72:537-47.
15. Clements JA, Nimmo WS. Pharmacokinetics and analgesic effect of ketamine in man. Br J Anaesth 1981;53:27-30.
16. Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults. JAMA 2012;307:1736-45.
17. Nassar MR, Rumsey KM, Wilson RC, et al. Rational regulation of learning dynamics by pupil-linked arousal systems. Nat Neurosci 2012;15:1040-6.
18. Zajonc RB. Emotion and facial efference: a theory reclaimed. Science 1985;228:15-21.
19. Ekman P, Levenson RW, Friesen WV. Autonomic nervous system activity distinguishes among emotions. Science 1983;221:1208-10.
20. Strack F, Martin LL, Stepper S. Inhibiting and facilitating conditions of the human smile: a nonobtrusive test of the facial feedback hypothesis. J Pers Soc Psychol 1988;54:768-77.
21. Larsen RJ, Kasimatis M, Frey K. Facilitating the furrowed brow: an unobtrusive test of the facial feedback hypothesis applied to unpleasant affect. Cogn Emot 1992;6:321-38.
22. Lewis MB, Bowler PJ. Botulinum toxin cosmetic therapy correlates with a more positive mood. J Cosmet Dermatol 2009;8:24-6.
23. Havas DA, Glenberg AM, Gutowski KA, et al. Cosmetic use of botulinum toxin-a affects processing of emotional language. Psychol Sci 2010;21:895-900.
24. Davis JI, Senghas A, Brandt F, et al. The effects of BOTOX injections on emotional experience. Emotion 2010;10:433-40.
25. Hennenlotter A, Dresel C, Castrop F, et al. The link between facial feedback and neural activity within central circuitries of emotion - new insights from botulinum toxin-induced denervation of frown muscles. Cereb Cortex 2009;19:537-42.
26. Studerus E, Kometer M, Hasler F, et al. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 2011;25:1434-52.
27. Griffiths RR, Richards WA, McCann U, et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 2006;187:268-83.
28. Griffiths R, Richards W, Johnson M, et al. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 2008;22:621-32.
29. Griffiths RR, Johnson M, Richards W, et al. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl) 2011;218:649-65.
30. MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 2011;25:1453-61.
31. Zarate CA, Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006;163:153-5.
32. Preskorn SH, Baker B, Kolluri S, et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008;28:631-7.
33. Ibrahim L, Diaz Granados N, Jolkovsky L, et al. A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol 2012;32:551-7.
34. Krebs TS, Johansen P-O. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol 2012;26:994-1002.
35. Studerus E, Gamma A, Kometer M, et al. Prediction of psilocybin response in healthy volunteers. PLoS ONE 2012;7:e30800.
36. Lee H-M, Roth BL. Hallucinogen actions on human brain revealed. Proc Natl Acad Sci U S A 2012;109:1820-1.
37. Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 2010;11:642-51.
38. Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 2012;109:2138-43.
39. Segal ZV, Williams JMG, Teasdale JD. Mindfulness-based cognitive therapy for depression: a new approach to preventing relapse. New York: Guilford Press; 2002.
40. Hölzel BK, Carmody J, Vangel M, et al. Mindfulness practice leads to increases in regional brain gray matter density. Psychiatry Res 2011;191:36-43.
41. Hölzel BK, Carmody J, Evans KC, et al. Stress reduction correlates with structural changes in the amygdala. Soc Cogn Affect Neurosci 2010;5:11-7.
42. Duman RS, Voleti B. Signaling pathways underlying the patho-physiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci 2012;35:47-56.
43. Li N, Liu R-J, Dwyer JM, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 2011;69:754-61.